Friday, 16 October 2026European Markets

PAREF, WERELDHAVE BELGIUM, Another 1 Companies Have A High Dividend Yield And Return On Equity In The Real Estate Sector.

Loading stream...

(vianews) - paref (par.pa) is among this list of stock assets with the highest dividend rate and return on equity on the real estate sector.

financial asset price forward dividend yield return on equity
paref (par.pa) €61.00 7.77% 2.78%
wereldhave belgium (wehb.br) €55.40 7.65% 8.05%
warehouses estates (web.br) €39.60 4.66% 10.19%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. paref (par.pa)

7.77% forward dividend yield and 2.78% return on equity

paref sa owns and manages business real estate located primarily in the paris region. the company manages and leases real estate, offices and commercial spaces, and residences. the company also provides real estate agency services. the company was founded in 1997 and is based in paris, france.

earnings per share

as for profitability, paref has a trailing twelve months eps of €13.91.

pe ratio

paref has a trailing twelve months price to earnings ratio of 4.39. meaning, the purchaser of the share is investing €4.39 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 2.78%.

more news about paref.

2. wereldhave belgium (wehb.br)

7.65% forward dividend yield and 8.05% return on equity

wereldhave belgium focuses on shopping centres and retail parks that are dominant in their catchment area. the shares are listed on the euronext brussels stock exchange. on 31 march 2020, wereldhave belgium's market capitalisation amounts to € 403 million.

earnings per share

as for profitability, wereldhave belgium has a trailing twelve months eps of €6.24.

pe ratio

wereldhave belgium has a trailing twelve months price to earnings ratio of 8.88. meaning, the purchaser of the share is investing €8.88 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 8.05%.

moving average

wereldhave belgium's worth is higher than its 50-day moving average of €54.58 and above its 200-day moving average of €51.02.

volatility

wereldhave belgium's last week, last month's, and last quarter's current intraday variation average was a positive 0.62%, a negative 0.07%, and a positive 1.12%.

wereldhave belgium's highest amplitude of average volatility was 2.33% (last week), 1.24% (last month), and 1.12% (last quarter).

yearly top and bottom value

wereldhave belgium's stock is valued at €55.40 at 07:30 est, way below its 52-week high of €62.00 and way above its 52-week low of €42.80.

more news about wereldhave belgium.

3. warehouses estates (web.br)

4.66% forward dividend yield and 10.19% return on equity

warehouses estates belgium sca is a real estate investment trust. warehouses estates belgium sca is based in belgium.

earnings per share

as for profitability, warehouses estates has a trailing twelve months eps of €5.42.

pe ratio

warehouses estates has a trailing twelve months price to earnings ratio of 7.31. meaning, the purchaser of the share is investing €7.31 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 10.19%.

more news about warehouses estates.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com